Radiant Innovation

Radiant Innovation CapEx/OCF

The CapEx to Operating Cash Flow Ratio of Radiant Innovation (3373.TWO) as of Nov 20, 2026 is 287.79 %. In the previous year, CapEx to Operating Cash Flow Ratio was 56.62 % — a change of 408.30% (higher).

CapEx/OCF

287.79 %

YoY

408.30%

Last updated:

CapEx to Operating Cash Flow Ratio of Radiant Innovation is 2025 287.79 % . CapEx to Operating Cash Flow Ratio of Radiant Innovation was 2024 56.62 % . It decreases by 408.30% higher compared to the previous year.

The Radiant Innovation CapEx/OCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CapEx/OCF
Date
CapEx/OCF
Jan 1, 2018
76.16 TWD
Jan 1, 2019
14.68 TWD
Jan 1, 2020
3.75 TWD
Jan 1, 2021
-17.06 TWD
Jan 1, 2022
-30.87 TWD
Jan 1, 2023
142.44 TWD
Jan 1, 2024
56.62 TWD
Jan 1, 2025
287.79 TWD
The Radiant Innovation CapEx/OCF history
YEARCapEx/OCFYoY
287.79 %+408.30%
56.62 %-60.25%
142.44 %-561.50%
-30.87 %+80.95%
-17.06 %-555.31%
3.75 %-74.48%
14.68 %-80.72%
76.16 %-244.18%
-52.83 %-472.83%
14.17 %-92.24%
182.50 %-226.86%
-143.86 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Radiant Innovation Stock analysis

What does Radiant Innovation do? Radiant Innovation Inc. generates revenue through the design, manufacture, and sale of infrared technology products. The company's main products include infrared temperature measurement instruments, ear temperature guns, frontal temperature guns, and other body temperature measurement products, alongside carbon dioxide detectors, infrared thermal imagers, and blood glucose dedicated chipsets. These products are distributed domestically and internationally across Asia, the Americas, Europe, and other regions. The primary buyers are healthcare providers, medical facilities, and electronic component distributors who require precise measurement tools and specialized components for health monitoring and diagnostics. The firm's product portfolio targets healthcare and industrial segments, with infrared thermal imagers used in building inspections and carbon dioxide detectors deployed in environmental monitoring. Blood glucose dedicated chipsets are supplied to medical device manufacturers for integration into diagnostic equipment. International distribution channels focus on regions like Asia, the Americas, and Europe, where demand for health-related measurement devices remains strong. Revenue streams are driven by direct sales to medical institutions, electronic component distributors, and industrial clients. The company's product lines serve both consumer-facing health monitoring applications and specialized industrial uses, with a strong emphasis on accuracy and reliability in temperature and gas detection technologies. Radiant Innovation is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Radiant Innovation stock

CapEx to Operating Cash Flow Ratio of Radiant Innovation is 287.79 % in 2025.

CapEx to Operating Cash Flow Ratio of Radiant Innovation changed from 56.62 % to 287.79 %, representing a 408.30% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of CapEx to Operating Cash Flow Ratio Radiant Innovation since 2006 – with annual values, charts, and detailed analysis.

The CapEx/OCF ratio shows what percentage of operating cash flow is reinvested in capital assets. Lower ratios indicate more free cash available for shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare CapEx to Operating Cash Flow Ratio's Radiant Innovation with sector peers and the industry average to assess whether it is attractive.

To evaluate CapEx to Operating Cash Flow Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for CapEx to Operating Cash Flow Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Radiant Innovation

All Key Metrics — Radiant Innovation